Pushing through on a plan to get out of the early-stage anti-infectives R&D space, AstraZeneca is spinning out its Waltham, MA-based company into an independent biotech, a move that will have an ...

WALTHAM - British drug maker AstraZeneca PLC on Monday announced a $100 million expansion of its facility here to boost research and development of drugs that treat cancer and infectious diseases.

Last summer, AstraZeneca formally spun out its pared-down early-stage antibiotics unit in Waltham, MA, as Entasis Therapeutics, bequeathing a $40 million A round for a launch after it failed to ...

The deal with AstraZeneca will extend to all of the company’s US sites by the end of 2026, and will start with purchasing renewable natural gas for a campus in Delaware.

Waltham-based AstraZeneca advance its TB drug developed in Waltham. UK-based drug giant AstraZeneca plc (NYSE: AZN) announced it has launched a Phase 2 clinical trial in South Africa with its ...

What’s up in Waltham? A renaissance, says its mayor. That rebirth includes an old Polaroid plant turned into a shopping and dining destination; luxury rental apartments rising above the city’s ...

AstraZeneca injecting $100M into Waltham lab. By Michelle Hillman and Mark Hollmer – Journal staff. Jul 24, 2006. Updated Jul 20, 2006 4:32pm EDT. Back to Top .

X-Chem Inc., a Waltham-based biotechnology company focused on developing small molecule drugs, said Thursday that it is expanding its collaboration with AstraZeneca PLC, a large Anglo-Swedish drug ...

LONDON (AP) — The board of pharmaceutical company AstraZeneca on Friday flatly rejected drug maker Pfizer’s sweetened takeover offer just hours after it was levelled, describing it as ...